Stan Berenshteyn

Q: What is Stan Berenshteyn's success rate?

Stan Berenshteyn currently has a success rate of 93.97858736587412.

Q: What is the average return of Stan Berenshteyn's calls?

Their stock ratings have generated an average return of 27.29664266638719.

Wells Fargo | Healthcare

Stan Berenshteyn is an analyst from Wells Fargo specializing in the Healthcare sector. Ranked #554 out of 4658 analysts, they have issued 32 stock ratings with a success rate of 93.98% and an average return of 27.30%.

Stan Berenshteyn has a well-established track record, with 32 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 93.98% and an average return of 27.30%, underscoring their expertise and ability to identify winning opportunities for investors.

#554

Out of 4658

Total Ratings

+93.98%

Success Rate

+27.30%

Average Return

Recent Ratings Analysis

PHR

Hold

May 20, 2026

Target

$9.00

Current

$8.85

Performance

0.00%

Stan Berenshteyn rated PHR as Equal-Weight on May 20, 2026, setting a price target of 9. The Hold stance appears justified, as shares hovered around 8.85 with a 0.00% move.

DOCS

Hold

May 14, 2026

Target

$18.00

Current

$19.86

Performance

10.27%

On May 14, 2026, DOCS was given a Equal-Weight rating by Stan Berenshteyn, with a target price of 18. The stock rallied from 19.86 to 19.86 after the Hold rating, surprising to the upside.

OMDA

Hold

May 08, 2026

Target

$18.00

Current

$16.52

Performance

11.47%

OMDA received a Equal-Weight rating from Stan Berenshteyn on May 08, 2026, aiming for 18. Investors saw gains of 11.47% that the cautious stance didn’t fully capture.

HNGE

Buy

May 06, 2026

Target

$80.00

Current

$54.74

Performance

-0.18%

On May 06, 2026, Stan Berenshteyn published a Overweight outlook on HNGE, with a target of 80. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 54.74.

OMCL

Buy

Apr 23, 2026

Target

$55.00

Current

$44.72

Performance

22.96%

Stan Berenshteyn on Apr 23, 2026 assigned OMCL a Overweight rating, with a price target of 55. The Buy call aligned well with market performance, producing a gain of 22.96%.

CTEV

Hold

Mar 19, 2026

Target

$22.00

Current

$21.24

Performance

38.46%

On Mar 19, 2026, Stan Berenshteyn reaffirmed CTEV with a Equal-Weight rating, targeting 22. Market strength beyond 21.24 went further than the conservative outlook suggested.

HCAT

Hold

Mar 18, 2026

Target

$1.00

Current

$1.29

Performance

11.21%

HCAT was rated Equal-Weight by Stan Berenshteyn on Mar 18, 2026, with a price objective of 1. Despite caution, upside momentum rewarded risk-takers with gains to 1.29.

VEEV

Buy

Mar 05, 2026

Target

$333.00

Current

$164.96

Performance

—

On Mar 05, 2026, Stan Berenshteyn initiated coverage on VEEV with a Overweight rating and target of 333. Neutral price movement of % leaves room for interpretation.

GDRX

Buy

Mar 04, 2026

Target

$7.00

Current

$2.52

Performance

—

Stan Berenshteyn issued a Overweight recommendation for GDRX on Mar 04, 2026, price target set at 7. The target of 7 remains in play, though confirmation will depend on future moves.

TDOC

Hold

Feb 26, 2026

Target

$8.00

Current

$6.48

Performance

21.12%

On Feb 26, 2026, TDOC was evaluated by Stan Berenshteyn, who gave a Equal-Weight rating and target of 8. Investors who stayed in despite the Hold saw upside of 21.12%.

WAY

Buy

Feb 19, 2026

Target

$41.00

Current

$19.21

Performance

-25.51%

Stan Berenshteyn rated WAY as Overweight on Feb 19, 2026, setting a price target of 41. The stock has underperformed, dropping 25.51% despite the bullish target of 41.

AMWL

Buy

Nov 05, 2025

Target

$9.00

Current

$7.89

Performance

72.65%

On Nov 05, 2025, AMWL was given a Overweight rating by Stan Berenshteyn, with a target price of 9. The stock rallied 72.65% after the rating, narrowing the gap to the target of 9 and validating the bullish stance.

HQY

Buy

Feb 26, 2025

Target

$125.00

Current

$87.55

Performance

-17.10%

HQY received a Overweight rating from Stan Berenshteyn on Feb 26, 2025, aiming for 125. The rating hasn’t played out as hoped, with the stock trading 17.10% below expectations.

ACCD

Hold

Oct 11, 2024

Target

$6.00

Current

$7.02

Performance

85.22%

On Oct 11, 2024, Stan Berenshteyn published a Equal-Weight outlook on ACCD, with a target of 6. The Hold call missed some of the bullish momentum as shares advanced toward 6.

Frequency Asked Questions

Who is Stan Berenshteyn?

Stan Berenshteyn is an analyst from Wells Fargo specializing in the Healthcare sector.

What is Stan Berenshteyn's success rate?

Stan Berenshteyn currently has a success rate of +93.98%.

How many ratings has Stan Berenshteyn issued?

Stan Berenshteyn has issued 32 stock ratings so far.

What is the average return of Stan Berenshteyn's calls?

Their stock ratings have generated an average return of +27.30%.

What is Stan Berenshteyn's ranking?

Stan Berenshteyn is ranked #554 out of 4658 analysts.

What types of ratings does Stan Berenshteyn give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Stan Berenshteyn?

You can follow Stan Berenshteyn by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Stan Berenshteyn?

Their latest rating was a Hold on PHR issued on 2026-05-20.